GlaxoSmithKline (GSK) has agreed to acquire the 80.02% of its proteomics research partner Cellzome that it does not already own for £61 M (US$98 M) in cash. The acquisition will expand GSK’s existing drug discovery platform and add to its capacity to characterise drug targets. Simultaneously, the two parties intend to create a spin-off company, which would hold the rights to certain Cellzome assets and activities that GSK does not wish to progress.